Befovacimab
Modify Date: 2024-01-10 17:52:38
Befovacimab structure
|
Common Name | Befovacimab | ||
|---|---|---|---|---|
| CAS Number | 2156634-62-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BefovacimabBefovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research[1]. |
| Name | Befovacimab |
|---|
| Description | Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Befovacimab 通过 K1 和 K2 结构域以高亲和力 (<10 pM) 结合人 TFPI，抑制其与 FXa 和 FVIIa 的相互作用，从而恢复它们的活性[1]。 |
| In Vivo | 在猴血浆中，Befovacimab 对游离 TFPI 和稀释的凝血酶原时间 (dPT) 的 IC50 分别为 4.65 nM 和 6.19 nM[1]。 Befovacimab（5 和 20 mg/kg；静脉和皮下给药）剂量依赖性降低体内雌性食蟹猴的 TFPI 浓度和凝血时间[1]。 |
| References |
| No Any Chemical & Physical Properties |